Axillary lymphadenopathy
In June 2021, FDA approved semaglutide as a treatment for chronic weight management in obese or overweight adultsthe first drug approved for such use since 2014
Current obesity medicine consensus holds that optimizing GLP-1 dosing delivers maximum benefit for most patients, making the combination unproven for incremental gain
She is the founder and executive director of the GLP-1 Collective, a nonprofit supporting patients through trusted resources, national support groups, and community education
Published Phase 2 studies provide controlled evidence, but longer-range characterization, broader population diversity, independent replication, and final regulatory review remain incomplete
Frequently Asked Questions Does semaglutide increase the risk of blood clots